CRISPR Therapeutics AG

Biological Products, (No Diagnostic Substances)·ZUG·FY end 12/31·CIK 1674416

CEO Pay Ratio

26:1

CEO Total Comp

—

Median Employee

$295,181

Revenue

$3.5M

FY 2025

Net Income

-$581.6M

FY 2025

Free Cash Flow

-$345.9M

FY 2025

Net Margin

-16569.8%

Insider Net (180d)

-$12.8M

0 buys / 22 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$3.5M	$37.3M	$371.2M	$1.2M	$915.0M
Gross Profit	—	—	—	—	—	—
Operating Income	-$664.6M	-$466.6M	-$222.5M	-$673.2M	$373.5M
Net Income	-$581.6M	-$366.3M	-$153.6M	-$650.2M	$377.7M
Operating CF	-$345.0M	-$142.8M	-$260.4M	-$495.7M	$539.0M
Capex	$914.0K	$1.9M	$9.5M	$37.2M	$81.7M
Free Cash Flow	-$345.9M	-$144.7M	-$269.8M	-$532.9M	$457.3M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	-18933.6%	-1250.4%	-60.0%	-56190.4%	40.8%
Net Margin	-16569.8%	-981.5%	-41.4%	-54271.7%	41.3%
FCF Margin	-9855.5%	-387.7%	-72.7%	-44484.9%	50.0%
R&D / Revenue	8114.1%	859.3%	104.3%	38534.6%	47.9%
Effective Tax	-0.6%	-1.0%	-1.9%	0.0%	0.5%
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
James R. Kasinger	$494.2K	—	$1.2M	$922.9K	$272.4K	$14.0K
Raju PrasadPh.D.	$493.5K	—	$1.9M	$922.9K	$272.0K	$14.0K
General Counsel	$479.8K	—	$3.3M	$2.1M	$263.4K	$13.8K
Julianne BrunoM.B.A.	$134.6K	—	$2.4M	$1.1M	—	$10.4K
Samarth KulkarniPh.D.	$768.6K	—	$3.5M	$2.8M	$659.1K	$7.0K
Naimish PatelM.D.	$551.0K	—	$2.3M	$1.2M	$303.8K	$3.7K